Intra-tumor heterogeneity (ITH) is a mechanism of therapeutic resistance and therefore an important clinical challenge. However, the extent, origin, and drivers of ITH across cancer types are poorly understood. To address this, we extensively characterize ITH across whole-genome sequences of 2,658 cancer samples spanning 38 cancer types. Nearly all informative samples (95.1%) contain evidence of distinct subclonal expansions with frequent branching relationships between subclones. We observe positive selection of subclonal driver mutations across most cancer types and identify cancer type-specific subclonal patterns of driver gene mutations, fusions, structural variants, and copy number alterations as well as dynamic changes in mutational p...
As sequencing efforts continue to reveal the extent of the intratumor heterogeneity (ITH) present in...
Recent advances in sequencing technologies have revealed extensive intratumour heterogeneity (ITH) b...
Genomic instability is a major driver of intra-tumor heterogeneity. However, unstable genomes often ...
Intra-tumor heterogeneity (ITH) is a mechanism of therapeutic resistance and therefore an important ...
Intra-tumor heterogeneity (ITH) is a mechanism of therapeutic resistance and therefore an important ...
Intratumor heterogeneity (ITH) drives neoplastic progression and therapeutic resistance. We used the...
Increasing evidence supports the existence of intratumor heterogeneity (ITH) in many cancer types, w...
Intratumor heterogeneity (ITH) drives neoplastic progression and therapeutic resistance. We used the...
Genomic instability is a major driver of intra-tumor heterogeneity. However, unstable genomes often ...
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article dis...
Molecular studies of intra-tumor heterogeneity (ITH) are revealing a large amount of DNA-based varia...
Intratumor genetic heterogeneity (ITH) is the main obstacle to effective cancer treatment and a majo...
Precision medicine requires an understanding of cancer genes and mutational processes, as well as an...
Advances in innovative technology, including next-generation sequencing, have allowed comprehensive ...
Assessing intra-tumoral heterogeneity (ITH) is of paramount importance to anticipate failure of targ...
As sequencing efforts continue to reveal the extent of the intratumor heterogeneity (ITH) present in...
Recent advances in sequencing technologies have revealed extensive intratumour heterogeneity (ITH) b...
Genomic instability is a major driver of intra-tumor heterogeneity. However, unstable genomes often ...
Intra-tumor heterogeneity (ITH) is a mechanism of therapeutic resistance and therefore an important ...
Intra-tumor heterogeneity (ITH) is a mechanism of therapeutic resistance and therefore an important ...
Intratumor heterogeneity (ITH) drives neoplastic progression and therapeutic resistance. We used the...
Increasing evidence supports the existence of intratumor heterogeneity (ITH) in many cancer types, w...
Intratumor heterogeneity (ITH) drives neoplastic progression and therapeutic resistance. We used the...
Genomic instability is a major driver of intra-tumor heterogeneity. However, unstable genomes often ...
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article dis...
Molecular studies of intra-tumor heterogeneity (ITH) are revealing a large amount of DNA-based varia...
Intratumor genetic heterogeneity (ITH) is the main obstacle to effective cancer treatment and a majo...
Precision medicine requires an understanding of cancer genes and mutational processes, as well as an...
Advances in innovative technology, including next-generation sequencing, have allowed comprehensive ...
Assessing intra-tumoral heterogeneity (ITH) is of paramount importance to anticipate failure of targ...
As sequencing efforts continue to reveal the extent of the intratumor heterogeneity (ITH) present in...
Recent advances in sequencing technologies have revealed extensive intratumour heterogeneity (ITH) b...
Genomic instability is a major driver of intra-tumor heterogeneity. However, unstable genomes often ...